Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug
03:08am, Tuesday, 27'th Sep 2022
AstraZeneca PLC (LSE:AZN) said its Tezspire treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids don't work. It is the third approval in a mat
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
12:47pm, Monday, 26'th Sep 2022
AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.
Should Growth Investors Buy This Little-Known Stock?
06:30am, Saturday, 24'th Sep 2022
Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.
3 Medical Stocks Displaying Remarkable Relative Strength in 2022
03:48pm, Friday, 23'rd Sep 2022
In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
09:41am, Friday, 23'rd Sep 2022
Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing. The post Ionis Pharmaceuticals Nosedives After AstraZeneca Drops Hig
AstraZeneca wins European approval for Ultomiris autoimmune disease treatment
04:38am, Friday, 23'rd Sep 2022
Ultomiris, the generalised myasthenia gravis (gMG) treatment developed by multinational pharmaceutical giant AstraZeneca PLC (LSE:AZN), has been approved for adult treatment in Europe. The nod from th
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
12:48pm, Thursday, 22'nd Sep 2022
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
AstraZeneca receives China green light for Lynparza
02:40am, Thursday, 22'nd Sep 2022
AstraZeneca PLC (LSE:AZN) said a drug it has developed jointly with Merck has been approved for use in women with advanced ovarian cancer by the Chinese authorities. Lynparza has been signed off as a
AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID
12:48pm, Wednesday, 21'st Sep 2022
Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.
AstraZeneca's Evusheld approved for treatment of Covid-19 in EU
02:43am, Tuesday, 20'th Sep 2022
AstraZeneca PLC (LSE:AZN) said its long-acting antibody combination Evusheld (tixagevimab and cilgavimab, formerly AZD7442) has been approved in the EU for the treatment of Covid-19. The approval b
AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID
12:02pm, Monday, 19'th Sep 2022
CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.
AstraZeneca gets EU backing for Covid-19 treatment and RSV drug
06:53am, Friday, 16'th Sep 2022
AstraZeneca PLC (LSE:AZN) shares were among the top risers on the FTSE 100 after it received a triple dose of good news, including backing from the European Union drug regulator for its Covid-19 trea
Market movers: AstraZeneca rises after EU drug approvals
03:46am, Friday, 16'th Sep 2022
AstraZeneca PLC (LSE:AZN) was a rare riser in the FTSE 100 after it said today it had received two recommendations for drug approvals in the EU, while a drug for blood disorder paroxysmal nocturnal ha
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
07:48am, Wednesday, 14'th Sep 2022
Shares in pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca were little changed Wednesday despite getting a ratings boost from analysts at Berenberg, who cited respective
Got $5,000? These 2 Stocks Are No-Brainer Buys.
10:37am, Thursday, 08'th Sep 2022
The stocks are profitable, stable, and pay dividends.
